Clinical Trial Update: Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating a four-drug regimen (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for multiple myeloma with ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extramedullary Plasmacytoma
• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Velcade (bortezomib)

Snippet

Sponsor: Stichting European Myeloma Network | Conditions: Multiple Myeloma, Extramedullary Plasmacytoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING